On the occasion of Republic Day on Thursday, Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh introduced the nasal Covid vaccine, iNCOVACC, from Bharat Biotech.
At Mandaviya’s residence, the first intranasal vaccine produced in India was introduced to the world.
The Drugs Controller General of India (DCGI) has approved the nasal vaccine, BBV154, in November for restricted emergency use among adults as a heterologous booster dose.
Bharat Biotech previously issued a statement stating that “iNCOVACC” is priced at Rs. 800 for private markets and at Rs. 325 for supplies to the Indian government and state governments.
Adenovirus-vectored vaccine called iNCOVACC has a spike protein that has been stabilised before fusing and recombinant replication deficiencies. The Hyderabad-based vaccine manufacturer had stated that this vaccine candidate had undergone successful evaluation in phase I, phase II, and phase III clinical trials.
The efficacy of iNCOVACC as a primary dose schedule and a heterologous booster dose for individuals who have already received two doses of either Covishield or Covaxin were assessed in clinical trials.